Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Breast 1

Conditions

Sarcoma 4Neoplasms 4Neoplasm Metastasis 3Melanoma 3Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Eyelid Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Doxorubicin 18Ifosfamide 13Radiotherapy 8Paclitaxel 7pazopanib 6pembrolizumab 4Gemcitabine 4Filgrastim 4Chemotherapy, Adjuvant 4Bevacizumab 4spartalizumab 3durvalumab 3Sorafenib 3Propranolol 3Nivolumab 3Ipilimumab 3Imatinib Mesylate 3Etoposide 3Epirubicin 3Docetaxel 3Carboplatin 3trebananib 2regorafenib 2cixutumumab 2cemiplimab 2carotuximab 2brostallicin 2belinostat 2balstilimab 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hemangiosarcoma × cemiplimab × Sarcoma × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04873375 2024-10-31

Cemiplimab for Secondary Angiosarcomas

Radboud University Medical Center

Phase 2 Completed
18 enrolled
Sarcoma

Hemangiosarcoma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡